News

CURE2d
FDA Approves Emrelis in Previously Treated, Advanced NSCLC
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...
Cancer Therapy Advisor2d
FDA Approves Emrelis for High c-Met Protein Overexpressing NSCLC
The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.
The American Journal of Managed Care1d
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...
STAT8d
FDA approves Verastem’s ovarian cancer treatment
Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...
The American Journal of Managed Care8d
FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC
FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...
WebMD16d
FDA Approves New Long-Term Treatment for Myasthenia Gravis
May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...
WebMD1d
FDA OKs New Treatment for Hard-to-Treat Lung Cancer
The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.
Yahoo Finance17d
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of ...